Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Jun-Dae Kim *Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA.
Surbhi Chaudhary *Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA.
Jonathan AstinDepartment of Molecular Medicine & Pathology, School of Medical Sciences, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0002-3554-0133
Philip S CrosierDepartment of Molecular Medicine & Pathology, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
Pengchun YuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
John P CookeCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0033-9138
Henry J PownallCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8412-506X
Hugo J BellenDepartment of Molecular and Human Genetics, Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5992-5989
Nhat-Tu LeCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA.
Daniel L KissCenter for RNA Therapeutics, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA.
Stanley G RocksonCenter for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1253-474X
Hong ChenVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. hong.chen@childrens.harvard.edu.ORCID http://orcid.org/0000-0003-1774-6549
Longhou FangCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute. Houston Methodist, Houston, TX, USA. lhfang@houstonmethodist.org.ORCID http://orcid.org/0000-0003-1653-5221
Funding
Epsin in Angiogenesis and Vascular RemodelingR01HL093242 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHEN, HONG, WANG, DA-ZHI · 2009 to 2021
$7.3M
Molecular Mechanisms Controlling Lymphatic Vascular Function in Health and DiseaseR01HL133216 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, DIXON, JAMES BRANDON · 2016 to 2025
$6.7M
Mechanisms regulating VEGF receptors in diabetic angiogenesisR01HL130845 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, XU, JIAN · 2016 to 2023
$4.9M
Premature aging disorders, metabolites, and atherosclerosisR01HL163857 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jun-Ichi Abe, JOHN P COOKE · 2023 to 2026
$2.9M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
AIBP Mediates a Novel Interplay between Cholesterol Metabolism and LymphangiogenesisR01HL132155 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI FANG, LONGHOU · 2016 to 2020
$2.7M
Metabolic mechanisms controlling lymphatic vessel formationR01HL162985 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI PENGCHUN YU · 2022 to 2026
$2.2M
American Heart Association (American Heart Association, Inc.) 18CDA34110132American Heart Association (American Heart Association, Inc.) 23IPA1050920American Heart Association (American Heart Association, Inc.) 24POST1242815American Heart Association-American Stroke Association 23IPA1050920NHLBI NIH HHS R01 HL093242NHLBI NIH HHS R01 HL130845NHLBI NIH HHS R01 HL132155NHLBI NIH HHS R01 HL133216NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R01 HL162985NHLBI NIH HHS R01 HL163857U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL093242U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL130845U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL132155U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL133216U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL148338
6 · The paper itself
Abstract
The lymphatic system maintains tissue fluid balance, and its dysfunction can result in lymphedema. Although cholesterol is essential for cellular function, its role in lymphatic development has remained unknown. Here, we identify APOA1 binding protein (AIBP) as a key regulator that promotes lymphatic endothelial cell fate specification and lymphangiogenesis. Mechanistically, AIBP reduces plasma membrane cholesterol content, thereby enhancing VEGFR3 signaling by disrupting caveolae-small plasma membrane invaginations formed by the scaffolding protein caveolin-1 (CAV-1)-and relieving CAV-1-mediated inhibition. In zebrafish and mice, AIBP loss impairs VEGFR3 signaling and lymphatic development, defects that can be rescued by CAV-1 deletion or by a VEGFR3 mutant (VEGFR3
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
APOA1 binding protein promotes lymphatic cell fate and lymphangiogenesis by relieving caveolae-mediated inhibition of VEGFR3 signaling. · full record | OpenQuestion